Not for distribution, directly or indirectly, in or into the United States
This press release shall not, and is not intended to, constitute an offer to sell or an invitation or solicitation of an offer to buy or subscribe for the securities of Peijia Medical Limited in the United States or any other jurisdiction. Securities may not be offered or sold in the United States absent registration under the United States Securities Act of 1933, as amended (the “Securities Act”) or an applicable exemption from the registration requirements of the Securities Act. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the issuer or selling security holder and that will contain detailed information about the Company and management, as well as financial statements. The securities referred to herein have not been and will not be registered under the Securities Act or any state securities laws of the United States, or under the applicable securities laws of Australia or Canada. No public offering of the securities referred to herein will be made in the United States or in any jurisdiction outside of Hong Kong. No copy of this press release has been or should be distributed or sent, directly or indirectly, to the United States, its territories or possessions.
This press release contains forward-looking statements and you are cautioned not to place undue reliance on any forward-looking statements contained herein. We can give no assurance that these forward-looking statements will prove to have been correct. Expectations reflected in these forward-looking statements are subject to change and we undertake no obligation and do not intend to update or revise any forward-looking statements herein.
Peijia Medical Announces Global Offering Results Offer Price is HK$15.36 per Offer Share
Commence Trading on the Main Board of the Hong Kong Stock Exchange On May 15, 2020
(Hong Kong, May 14, 2020) A major player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets – Peijia Medical Limited (“Peijia Medical” or the “Company”, together with its subsidiaries, the “Group”, stock code: 9996), today announced the allotment results of its share offering. The Company’s shares will commence trading on the Main Board of The Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange”) on May 15, 2020 (Friday) under the stock code of 9996.
The Offer Price of Peijia Medical is HK$15.36 per Offer Share. The net proceeds to be received by the Company is estimated to be approximately HK2,200.3 million from the Global Offering (after deduction of underwriting fees, commissions and estimated expenses payable by the Company in connection with the Global Offering and assuming the Over-allotment Option is not exercised). The Hong Kong Offer Shares have been very significantly over-subscribed. A total of 286,369 valid applications have been received for a total of 18,064,609,000 Hong Kong Offer Shares, representing approximately 1,184.41 times of the total number of 15,252,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering. The International Offering have been very significantly over-subscribed by 20 times. The final number of Offer Shares under the International Offering is 76,255,000 Shares, representing approximately 50% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).
The net proceeds are expected to be used for development and commercialization of the Group’s Core Product, TaurusOne®; the development and commercialization of the Group’s other major product candidates, including TaurusElite, TaurusNXT and Shenyi® Stent Retriever; the Group’s ongoing pre-clinical studies and planned clinical trials, preparation for registration filings and potential commercial launches (including sales and marketing) of the other product candidates in the Group’s pipeline; strengthening the Group’s research and development capabilities to enrich its product pipeline; expanding the Group’s product portfolio and intellectual property portfolio through potential strategic acquisitions, investments, partnership and licensing opportunities; and working capital and other general corporate purposes.
Dr. Yi Zhang, Executive Director, Chairman of the Board, Chief Executive Officer and Chief Technology Officer of Peijia Medical Limited, said, “We are very grateful for the enthusiastic support and attention from all the investors. Listing in Hong Kong not only allows Peijia Medical to enter into the international capital markets but also provides sufficient funds for the long-term development of the Group to grasp future development opportunities in the industry. In the future, we will continue to focus on the research and development of transcatheter valve therapeutic medical devices and neurointerventional procedural medical devices and strive to become a well-known medical device platform that provides treatment solutions for structural heart and neurovascular diseases.
– End –
About Peijia Medical Limited
Peijia Medical Limited is a leading domestic player in each of the transcatheter valve therapeutic medical device market and neurointerventional procedural medical device market in China. It focuses on the high-growth interventional procedural medical device market in China. Peijia Medical has built a synergetic platform encompassing research and development, manufacturing and commercialization capabilities as well as a series of product portfolio. Reverence for life, perseverance on innovation: Peijia Medical is committed to becoming a world-renowned medical device company that provides a series of product portfolio for structural heart and neurovascular diseases.
Issued by Porda Havas International Finance Communications Group for and on behalf of Peijia Medical Limited. For further information, please contact:
Porda Havas International Finance Communications Group
Terence Wong +852 3150 6773 terence.wong@pordahavas.com
Phoenix Fung +852 3150 6786 phoenix.fung@pordahavas.com
Christy Ng +852 3120 6515 christy.ng@pordahavas.com
Renee Zheng +852 3150 6755 r.zheng@pordahavas.com
Yoyo Chan +852 3150 6753 yoyo.chan@pordahavas.com
Fax: +852 3150 6728
